News | March 30, 2009

GE, Archimedes to Collaborate on Coronary Heart Disease Screening Study

March 30, 2009 - GE Healthcare and Archimedes Inc., an independent Healthcare Modeling organization, announced at ACC that they will collaborate to launch a new virtual study to identify an enhanced diagnostic protocol for predicting coronary heart disease (CHD).

The virtual study applies a sophisticated computer model which simulates diagnostic methods for screening and predicting heart disease to help researchers better understand earlier treatments for the number one killer among men and women in the U.S.

Claudio Marelli, M.D., F.A.C.C., strategic medical leader for GE Healthcare said, “The Framingham score fails to predict 25 percent of coronary artery disease. Unconditional treatment might expose patients to unbeneficial treatments. Our collaboration with Archimedes will shed light on the cost-benefit of screening strategies for CHD - and on the value of imaging - to increase current risk stratification capacities to adjust the intensity of treatment accordingly.”

Despite recent progress in the screening and prevention of CHD, many people continue to be improperly identified through current risk measurement tools such as the Framingham Risk Score. The collaboration will allow for the evaluation of screening strategies to determine the potential of an improved model for calculating the risk of CHD based on new technologies and risk factors.

“Leading innovators like GE Healthcare are embracing healthcare modeling,” said Barbara Peskin, principal investigator for Archimedes. “We are delighted to partner with GE Healthcare in its commitment to investigating preventive health through the use of the Archimedes Model.”

For more information: www.gehealthcare.com and www.archimedes.com

Related Content

A CT calcium scoring image showing calcified plaques in coronary vessel segments. The higher the calcium content of the vessels, the high risk the patient is for a heart attack event. CAC exam

A CT calcium scoring image showing calcified plaques in coronary vessel segments. The higher the calcium content of the vessels, the higher risk the patient is for a heart attack event. Image courtesy of Canon Medical Systems.

Feature | Computed Tomography (CT) | October 17, 2018 | Dave Fornell, Editor
A picture is worth a thousand words, and to patients concerned about their health, detailed images of the coronary an
Abdominal Aortic Calcification May Signal Future Heart Attack

Image from computed tomography (CT) colonography shows segmented abdominal aortic calcification measured with semiautomated CT tool on coronal image. Within region of interest over aorta selected by user, tool automatically segments and quantifies aortic calcification (shown in blue). 

Image Credit: O’Connor S D, Graffy P M, Zea R, et al. Does nonenhanced CT-based quantification of abdominal aortic calcification outperform the Framingham Risk Score in predicting cardiovascular event sin asymptomatic adults? Radiology doi: 10.1148/radiol.2018180562. Published online Oct. 2, 2018. © RSNA.

News | Computed Tomography (CT) | October 12, 2018
Computed tomography (CT)-based measures of calcification in the abdominal aorta are strong predictors of heart attacks...
Siemens Healthineers Announces First U.S. Install of Somatom go.Top CT
News | Computed Tomography (CT) | September 17, 2018
September 17, 2018 — The Ohio State University Wexner Medical Center in Columbus recently became the first healthcare
Key Patient Preparations for a CT Scan
News | Computed Tomography (CT) | September 05, 2018
The Center for Diagnostic Imaging (CDI) in Miami recently released a list of important preparations patients should...
Videos | Computed Tomography (CT) | July 25, 2018
A discussion with Patricia Dickson, LRT(CT), director of imaging and outpatient services, Capital Cardiology Associat
Videos | Computed Tomography (CT) | July 23, 2018
Ed Nicol, M.D., FSCCT, MBA, head of cardiac CT, Royal Brompton Hospital, London, and chair of the Society of Cardiova
Videos | Computed Tomography (CT) | July 17, 2018
An interview with Patrick Serruys, M.D., Ph.D., Imperial College London, principal investigator of the SYNTAX III Tri
Zebra Medical Vision Announces FDA 510(k) Clearance of Coronary Calcium Algorithm
Technology | Computed Tomography (CT) | July 12, 2018
Zebra Medical Vision has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Coronary...
Overlay Init